Belgian biotech founded by University of Torino team nabs $23.5 million in Series A round
Having spent more than two decades researching biology of the hepatocyte growth factor (HGF), Paolo Michieli and his team at the University of Torino, Italy forged a collaboration with Netherlands-based biotech Argenyx to create AgomAb Therapeutics in 2017. On Wednesday, the Belgian firm scored a €21 million (about $23.5 million) injection for its slate of undisclosed preclinical programs.
HGF — a protein secreted by mesenchymal cells — has long been studied for its role in cell proliferation, survival, motility and differentiation. It is understood to promote wound healing as well as tissue regeneration in a number of preclinical models, chief Tim Knotnerus said in an interview with Endpoints News.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
